Benjamin Lebwohl1, Karl Michaëlsson, Peter H R Green, Jonas F Ludvigsson. 1. Celiac Disease Center (B.L., P.H.R.G.), Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10027; Clinical Epidemiology Unit (B.L., J.F.L.), Department of Medicine, Karolinska University Hospital and Karolinska Institutet, SE-171 77 Stockholm, Sweden; Department of Surgical Sciences (K.M.), Section of Orthopaedics, Uppsala University, SE-751 05 Uppsala, Sweden; and Department of Pediatrics (J.F.L.), Örebro University Hospital, SE-70185; Örebro, Sweden.
Abstract
CONTEXT: Celiac disease (CD) is associated with an increased fracture risk, an increase that persists after diagnosis. A significant proportion of patients with CD have persistent villous atrophy (VA) on follow-up biopsy. OBJECTIVE: The objective of the study was to determine whether persistent VA impacts long-term fracture risk. DESIGN: This was a cohort study. SETTING AND PATIENTS: We identified all patients in Sweden with histological evidence of CD who underwent a follow-up biopsy and compared patients with persistent VA with those with mucosal healing. MAIN OUTCOME MEASURES: The following were measured: 1) any fracture; 2) likely osteoporotic fracture (defined as fractures of the hip, distal forearm, thoracic and lumbar spine, or proximal humerus); and 3) hip fracture. RESULTS: Of 7146 patients, VA was present on follow-up biopsy in 43%. There was no significant association between persistent VA and overall fractures [hazard ratio (HR) of persistent VA compared with those with healing 0.93, 95% confidence interval (CI) 0.82-1.06] or with likely osteoporotic fractures (HR 1.11, 95% CI 0.84-1.46). Persistent VA was associated with an increased risk of hip fracture (HR 1.67, 95% CI 1.05-2.66). Hip fracture risk increased, depending on the degree of VA (HR for partial VA compared with those with healing 1.70, 95% CI 0.82-3.49, HR for subtotal/total VA compared with those with healing 2.16, 95% CI 1.06-4.41). CONCLUSIONS: Persistent VA on follow-up biopsy is predictive of hip fracture risk. The association between persistent VA and hip fractures, but not fractures overall, implies that thinner sc tissue and fall or trauma may be mechanisms by which persistent VA confers an increased fracture risk.
CONTEXT: Celiac disease (CD) is associated with an increased fracture risk, an increase that persists after diagnosis. A significant proportion of patients with CD have persistent villous atrophy (VA) on follow-up biopsy. OBJECTIVE: The objective of the study was to determine whether persistent VA impacts long-term fracture risk. DESIGN: This was a cohort study. SETTING AND PATIENTS: We identified all patients in Sweden with histological evidence of CD who underwent a follow-up biopsy and compared patients with persistent VA with those with mucosal healing. MAIN OUTCOME MEASURES: The following were measured: 1) any fracture; 2) likely osteoporotic fracture (defined as fractures of the hip, distal forearm, thoracic and lumbar spine, or proximal humerus); and 3) hip fracture. RESULTS: Of 7146 patients, VA was present on follow-up biopsy in 43%. There was no significant association between persistent VA and overall fractures [hazard ratio (HR) of persistent VA compared with those with healing 0.93, 95% confidence interval (CI) 0.82-1.06] or with likely osteoporotic fractures (HR 1.11, 95% CI 0.84-1.46). Persistent VA was associated with an increased risk of hip fracture (HR 1.67, 95% CI 1.05-2.66). Hip fracture risk increased, depending on the degree of VA (HR for partial VA compared with those with healing 1.70, 95% CI 0.82-3.49, HR for subtotal/total VA compared with those with healing 2.16, 95% CI 1.06-4.41). CONCLUSIONS: Persistent VA on follow-up biopsy is predictive of hip fracture risk. The association between persistent VA and hip fractures, but not fractures overall, implies that thinner sc tissue and fall or trauma may be mechanisms by which persistent VA confers an increased fracture risk.
Authors: John A Kanis; Anders Oden; Helena Johansson; Fredrik Borgström; Oskar Ström; Eugene McCloskey Journal: Bone Date: 2009-02-03 Impact factor: 4.398
Authors: Patrick Haentjens; Jay Magaziner; Cathleen S Colón-Emeric; Dirk Vanderschueren; Koen Milisen; Brigitte Velkeniers; Steven Boonen Journal: Ann Intern Med Date: 2010-03-16 Impact factor: 25.391
Authors: María Inés Pinto Sánchez; Adriana Mohaidle; Andrea Baistrocchi; Dolores Matoso; Horacio Vázquez; Andrea González; Roberto Mazure; Evangelina Maffei; Guillermina Ferrari; Edgardo Smecuol; Adriana Crivelli; Juan Andrés de Paula; Juan C Gómez; Silvia Pedreira; Eduardo Mauriño; Julio César Bai Journal: World J Gastroenterol Date: 2011-07-07 Impact factor: 5.742
Authors: K Kaukinen; M Peräaho; K Lindfors; J Partanen; N Woolley; P Pikkarainen; A-L Karvonen; T Laasanen; H Sievänen; M Mäki; P Collin Journal: Aliment Pharmacol Ther Date: 2007-05-15 Impact factor: 8.171
Authors: Benjamin Lebwohl; Fredrik Granath; Anders Ekbom; Karin E Smedby; Joseph A Murray; Alfred I Neugut; Peter H R Green; Jonas F Ludvigsson Journal: Ann Intern Med Date: 2013-08-06 Impact factor: 25.391
Authors: Jonas F Ludvigsson; Eva Andersson; Anders Ekbom; Maria Feychting; Jeong-Lim Kim; Christina Reuterwall; Mona Heurgren; Petra Otterblad Olausson Journal: BMC Public Health Date: 2011-06-09 Impact factor: 3.295
Authors: Carolina Ciacci; Paul Ciclitira; Marios Hadjivassiliou; Katri Kaukinen; Jonas F Ludvigsson; Norma McGough; David S Sanders; Jeremy Woodward; Jonathan N Leonard; Gillian L Swift Journal: United European Gastroenterol J Date: 2015-04 Impact factor: 4.623
Authors: Jonas F Ludvigsson; Tim Card; Paul J Ciclitira; Gillian L Swift; Ikram Nasr; David S Sanders; Carolina Ciacci Journal: United European Gastroenterol J Date: 2015-04 Impact factor: 4.623
Authors: Haley M Zylberberg; Benjamin Lebwohl; Arindam RoyChoudhury; Marcella D Walker; Peter H R Green Journal: Endocrine Date: 2017-12-11 Impact factor: 3.633
Authors: Benjamin Lebwohl; Peter H R Green; Jonas Söderling; Bjorn Roelstraete; Jonas F Ludvigsson Journal: JAMA Date: 2020-04-07 Impact factor: 56.272
Authors: Emily M Stein; Halley Rogers; Alexa Leib; Donald J McMahon; Polly Young; Kyle Nishiyama; X Edward Guo; Suzanne Lewis; Peter H Green; Elizabeth Shane Journal: J Clin Endocrinol Metab Date: 2015-04-13 Impact factor: 5.958